title: Lung Cancer Biomarkers.
abstract: The molecular characterization of lung cancer has changed the classification and treatment of these tumors, becoming an essential component of pathologic diagnosis and oncologic therapy decisions. Through the recognition of novel biomarkers, such as epidermal growth factor receptor mutations and anaplastic lymphoma kinase translocations, it is possible to identify subsets of patients who benefit from targeted molecular therapies. The success of targeted anticancer therapies and new immunotherapy approaches has created a new paradigm of personalized therapy and has led to accelerated development of new drugs for lung cancer treatment. This article focuses on clinically relevant cancer biomarkers as targets for therapy and potential new targets for drug development.
authors.affiliation: Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, 2130 Holcombe Boulevard, Unit 2951, Houston, TX 77030, USA.
authors.forename: Pamela
authors.initials: P
authors.lastname: Villalobos
authors.affiliation: Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, 2130 Holcombe Boulevard, Unit 2951, Houston, TX 77030, USA. Electronic address: iiwistuba@mdanderson.org.
authors.forename: Ignacio I
authors.initials: II
authors.lastname: Wistuba
mesh_terms: D014408:Biomarkers, Tumor / Q000235:genetics*; D055808:Drug Discovery / Q000379:methods; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D008175:Lung Neoplasms / Q000235:genetics* / Q000473:pathology / Q000628:therapy
chemical_list: D014408:Biomarkers, Tumor
keywords: Biomarkers; Genotyping; Lung cancer; Molecular targets